Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares shot up 3.6% during trading on Tuesday . The stock traded as high as $8.75 and last traded at $8.75. 5,711 shares traded hands during mid-day trading, an increase of 85% from the average session volume of 3,082 shares. The stock had previously closed at $8.45.
Clinuvel Pharmaceuticals Stock Performance
The stock has a 50-day simple moving average of $7.62 and a 200-day simple moving average of $7.52.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
Featured Stories
- Five stocks we like better than Clinuvel Pharmaceuticals
- The boring AI play that could pay up to $4,290 monthly
- Put $1,000 into this stock by Jan 1 [Not NVDA]
- Trump’s “real estate deal for America” explained
- A month before the crash
- Trump Did WHAT??
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=54&w=95&zc=2){kind=logo}
